| Dr Aiman M Mahmood, MD | |
|
1500 E Medical Center Dr, Med Inn C728, Ann Arbor, MI 48109-5000 | |
| (734) 998-0891 | |
| Not Available |
| Full Name | Dr Aiman M Mahmood |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 20 Years |
| Location | 1500 E Medical Center Dr, Ann Arbor, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003170739 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 4301100066 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mclaren Port Huron | Port huron, MI | Hospital |
| Genesys Regional Medical Center - Health Park | Grand blanc, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sound Inpatient Physicians-michigan Pllc | 5395896849 | 213 |
News Archive
Health Net Federal Services, LLC, part of the Government Contracts segment of Health Net, Inc. today announced it was re-awarded three Patient Appointing Services bridge contracts, continuing its Patient Appointing Services work in Fort Irwin and Puget Sound through March 31, 2011, and in Great Lakes through January 31, 2011, by the United States Army's Center for Health Care Contracting, Fort Sam Houston, Texas. Each contract includes an option to extend services for an additional six months.
A possible diagnostic use for clot-dissolving drugs such as tPA has been found by Medical College of Georgia researchers working to improve a test that identifies potentially deadly blood clots in the legs.
Noting "the U.S. Food and Drug Administration (FDA) recently announced that it has approved a new treatment for multidrug-resistant tuberculosis (TB) that can be used as an alternative when other drugs fail," Kim Lufkin, communications officer at the Global Health Technologies Coalition (GHTC), writes in the coalition's "Breakthroughs" blog, "There is a pressing and urgent need for even more new TB drugs, which makes this new FDA approval so significant."
Cardinal Health today announced that it will manufacture and distribute Amyvid, Eli Lilly and Company's new diagnostic imaging agent that aids in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline. The commercial launch of Amyvid is scheduled for June 1, 2012.
A mechanism that regulates stem-cell differentiation in mice testes suggests a similar process that may trigger degenerative disease in humans, according to a Penn State College of Agricultural Sciences reproductive physiologist.
› Verified 9 days ago
| Entity Name | Munson Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083761860 PECOS PAC ID: 3072426287 Enrollment ID: O20040108000904 |
News Archive
Health Net Federal Services, LLC, part of the Government Contracts segment of Health Net, Inc. today announced it was re-awarded three Patient Appointing Services bridge contracts, continuing its Patient Appointing Services work in Fort Irwin and Puget Sound through March 31, 2011, and in Great Lakes through January 31, 2011, by the United States Army's Center for Health Care Contracting, Fort Sam Houston, Texas. Each contract includes an option to extend services for an additional six months.
A possible diagnostic use for clot-dissolving drugs such as tPA has been found by Medical College of Georgia researchers working to improve a test that identifies potentially deadly blood clots in the legs.
Noting "the U.S. Food and Drug Administration (FDA) recently announced that it has approved a new treatment for multidrug-resistant tuberculosis (TB) that can be used as an alternative when other drugs fail," Kim Lufkin, communications officer at the Global Health Technologies Coalition (GHTC), writes in the coalition's "Breakthroughs" blog, "There is a pressing and urgent need for even more new TB drugs, which makes this new FDA approval so significant."
Cardinal Health today announced that it will manufacture and distribute Amyvid, Eli Lilly and Company's new diagnostic imaging agent that aids in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline. The commercial launch of Amyvid is scheduled for June 1, 2012.
A mechanism that regulates stem-cell differentiation in mice testes suggests a similar process that may trigger degenerative disease in humans, according to a Penn State College of Agricultural Sciences reproductive physiologist.
› Verified 9 days ago
| Entity Name | Mclaren Central Michigan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245266063 PECOS PAC ID: 6103733092 Enrollment ID: O20040309000447 |
News Archive
Health Net Federal Services, LLC, part of the Government Contracts segment of Health Net, Inc. today announced it was re-awarded three Patient Appointing Services bridge contracts, continuing its Patient Appointing Services work in Fort Irwin and Puget Sound through March 31, 2011, and in Great Lakes through January 31, 2011, by the United States Army's Center for Health Care Contracting, Fort Sam Houston, Texas. Each contract includes an option to extend services for an additional six months.
A possible diagnostic use for clot-dissolving drugs such as tPA has been found by Medical College of Georgia researchers working to improve a test that identifies potentially deadly blood clots in the legs.
Noting "the U.S. Food and Drug Administration (FDA) recently announced that it has approved a new treatment for multidrug-resistant tuberculosis (TB) that can be used as an alternative when other drugs fail," Kim Lufkin, communications officer at the Global Health Technologies Coalition (GHTC), writes in the coalition's "Breakthroughs" blog, "There is a pressing and urgent need for even more new TB drugs, which makes this new FDA approval so significant."
Cardinal Health today announced that it will manufacture and distribute Amyvid, Eli Lilly and Company's new diagnostic imaging agent that aids in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline. The commercial launch of Amyvid is scheduled for June 1, 2012.
A mechanism that regulates stem-cell differentiation in mice testes suggests a similar process that may trigger degenerative disease in humans, according to a Penn State College of Agricultural Sciences reproductive physiologist.
› Verified 9 days ago
| Entity Name | Hospitalist Medicine Physicians Of Michigan Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013180181 PECOS PAC ID: 4486703170 Enrollment ID: O20090529000290 |
News Archive
Health Net Federal Services, LLC, part of the Government Contracts segment of Health Net, Inc. today announced it was re-awarded three Patient Appointing Services bridge contracts, continuing its Patient Appointing Services work in Fort Irwin and Puget Sound through March 31, 2011, and in Great Lakes through January 31, 2011, by the United States Army's Center for Health Care Contracting, Fort Sam Houston, Texas. Each contract includes an option to extend services for an additional six months.
A possible diagnostic use for clot-dissolving drugs such as tPA has been found by Medical College of Georgia researchers working to improve a test that identifies potentially deadly blood clots in the legs.
Noting "the U.S. Food and Drug Administration (FDA) recently announced that it has approved a new treatment for multidrug-resistant tuberculosis (TB) that can be used as an alternative when other drugs fail," Kim Lufkin, communications officer at the Global Health Technologies Coalition (GHTC), writes in the coalition's "Breakthroughs" blog, "There is a pressing and urgent need for even more new TB drugs, which makes this new FDA approval so significant."
Cardinal Health today announced that it will manufacture and distribute Amyvid, Eli Lilly and Company's new diagnostic imaging agent that aids in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline. The commercial launch of Amyvid is scheduled for June 1, 2012.
A mechanism that regulates stem-cell differentiation in mice testes suggests a similar process that may trigger degenerative disease in humans, according to a Penn State College of Agricultural Sciences reproductive physiologist.
› Verified 9 days ago
| Entity Name | Sound Inpatient Physicians-michigan Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639311996 PECOS PAC ID: 5395896849 Enrollment ID: O20090624000252 |
News Archive
Health Net Federal Services, LLC, part of the Government Contracts segment of Health Net, Inc. today announced it was re-awarded three Patient Appointing Services bridge contracts, continuing its Patient Appointing Services work in Fort Irwin and Puget Sound through March 31, 2011, and in Great Lakes through January 31, 2011, by the United States Army's Center for Health Care Contracting, Fort Sam Houston, Texas. Each contract includes an option to extend services for an additional six months.
A possible diagnostic use for clot-dissolving drugs such as tPA has been found by Medical College of Georgia researchers working to improve a test that identifies potentially deadly blood clots in the legs.
Noting "the U.S. Food and Drug Administration (FDA) recently announced that it has approved a new treatment for multidrug-resistant tuberculosis (TB) that can be used as an alternative when other drugs fail," Kim Lufkin, communications officer at the Global Health Technologies Coalition (GHTC), writes in the coalition's "Breakthroughs" blog, "There is a pressing and urgent need for even more new TB drugs, which makes this new FDA approval so significant."
Cardinal Health today announced that it will manufacture and distribute Amyvid, Eli Lilly and Company's new diagnostic imaging agent that aids in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline. The commercial launch of Amyvid is scheduled for June 1, 2012.
A mechanism that regulates stem-cell differentiation in mice testes suggests a similar process that may trigger degenerative disease in humans, according to a Penn State College of Agricultural Sciences reproductive physiologist.
› Verified 9 days ago
| Entity Name | Hospitalist Medicine Physicians Of Michigan - Port Huron, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285279919 PECOS PAC ID: 0244668598 Enrollment ID: O20200319001492 |
News Archive
Health Net Federal Services, LLC, part of the Government Contracts segment of Health Net, Inc. today announced it was re-awarded three Patient Appointing Services bridge contracts, continuing its Patient Appointing Services work in Fort Irwin and Puget Sound through March 31, 2011, and in Great Lakes through January 31, 2011, by the United States Army's Center for Health Care Contracting, Fort Sam Houston, Texas. Each contract includes an option to extend services for an additional six months.
A possible diagnostic use for clot-dissolving drugs such as tPA has been found by Medical College of Georgia researchers working to improve a test that identifies potentially deadly blood clots in the legs.
Noting "the U.S. Food and Drug Administration (FDA) recently announced that it has approved a new treatment for multidrug-resistant tuberculosis (TB) that can be used as an alternative when other drugs fail," Kim Lufkin, communications officer at the Global Health Technologies Coalition (GHTC), writes in the coalition's "Breakthroughs" blog, "There is a pressing and urgent need for even more new TB drugs, which makes this new FDA approval so significant."
Cardinal Health today announced that it will manufacture and distribute Amyvid, Eli Lilly and Company's new diagnostic imaging agent that aids in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline. The commercial launch of Amyvid is scheduled for June 1, 2012.
A mechanism that regulates stem-cell differentiation in mice testes suggests a similar process that may trigger degenerative disease in humans, according to a Penn State College of Agricultural Sciences reproductive physiologist.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Aiman M Mahmood, MD 4967 Crooks Rd, Ste 130, Troy, MI 48098-5801 Ph: (248) 952-1601 | Dr Aiman M Mahmood, MD 1500 E Medical Center Dr, Med Inn C728, Ann Arbor, MI 48109-5000 Ph: (734) 998-0891 |
News Archive
Health Net Federal Services, LLC, part of the Government Contracts segment of Health Net, Inc. today announced it was re-awarded three Patient Appointing Services bridge contracts, continuing its Patient Appointing Services work in Fort Irwin and Puget Sound through March 31, 2011, and in Great Lakes through January 31, 2011, by the United States Army's Center for Health Care Contracting, Fort Sam Houston, Texas. Each contract includes an option to extend services for an additional six months.
A possible diagnostic use for clot-dissolving drugs such as tPA has been found by Medical College of Georgia researchers working to improve a test that identifies potentially deadly blood clots in the legs.
Noting "the U.S. Food and Drug Administration (FDA) recently announced that it has approved a new treatment for multidrug-resistant tuberculosis (TB) that can be used as an alternative when other drugs fail," Kim Lufkin, communications officer at the Global Health Technologies Coalition (GHTC), writes in the coalition's "Breakthroughs" blog, "There is a pressing and urgent need for even more new TB drugs, which makes this new FDA approval so significant."
Cardinal Health today announced that it will manufacture and distribute Amyvid, Eli Lilly and Company's new diagnostic imaging agent that aids in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline. The commercial launch of Amyvid is scheduled for June 1, 2012.
A mechanism that regulates stem-cell differentiation in mice testes suggests a similar process that may trigger degenerative disease in humans, according to a Penn State College of Agricultural Sciences reproductive physiologist.
› Verified 9 days ago
Nabil Alkhoury Fallouh, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1500 East Medical Center Dr, 3rd Floor Taubman Ctr Recp B, Ann Arbor, MI 48109 Phone: 734-936-5582 | |
Sameer Dev Saini, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Dr. David Alexander Stewart, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 1500 E Medical Center Dr, 12th Floor C.s. Mott Children's Hospital Room 525, Ann Arbor, MI 48109 Phone: 734-763-5302 Fax: 734-647-5624 | |
Anastasia Irene Wasylyshyn, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Katherine Saber Salisbury, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4260 Plymouth Rd, Ann Arbor, MI 48109 Phone: 734-764-6831 | |
Anne Lewis Carlton, Internal Medicine Medicare: Medicare Enrolled Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-647-5900 |